These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 25698097

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
    Zhao YJ, Chen WX, Wu DS, Zhang WY, Zheng LR.
    Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
    Sammon J, Fischer S, Menezes R, Hosseini-Nik H, Lewis S, Taouli B, Jhaveri K.
    Cancer Imaging; 2018 Feb 27; 18(1):8. PubMed ID: 29486800
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Chong YS, Kim YK, Lee MW, Kim SH, Lee WJ, Rhim HC, Lee SJ.
    Clin Radiol; 2012 Aug 27; 67(8):766-73. PubMed ID: 22425613
    [Abstract] [Full Text] [Related]

  • 9. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.
    Kim SH, Lee CH, Kim BH, Kim WB, Yeom SK, Kim KA, Park CM.
    J Comput Assist Tomogr; 2012 Aug 27; 36(6):704-9. PubMed ID: 23192208
    [Abstract] [Full Text] [Related]

  • 10. Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI.
    Chang AI, Kim YK, Min JH, Lee J, Kim H, Lee SJ.
    Abdom Radiol (NY); 2019 Apr 27; 44(4):1395-1406. PubMed ID: 30515535
    [Abstract] [Full Text] [Related]

  • 11. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH, Kim SH, Park MJ, Park CK, Rhim H.
    AJR Am J Roentgenol; 2011 Nov 27; 197(5):W868-75. PubMed ID: 22021534
    [Abstract] [Full Text] [Related]

  • 12. Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.
    Kovač JD, Janković A, Đikić-Rom A, Grubor N, Antić A, Dugalić V.
    Curr Oncol; 2022 Jan 30; 29(2):698-723. PubMed ID: 35200560
    [Abstract] [Full Text] [Related]

  • 13. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J, Kim YK, Park MJ, Lee MH, Kim SH, Lee WJ, Rhim HC.
    J Magn Reson Imaging; 2012 Oct 30; 36(4):881-9. PubMed ID: 22730271
    [Abstract] [Full Text] [Related]

  • 14. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Abdom Imaging; 2015 Aug 30; 40(6):1492-9. PubMed ID: 25579172
    [Abstract] [Full Text] [Related]

  • 15. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.
    Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J.
    Hepatology; 2009 Sep 30; 50(3):791-8. PubMed ID: 19610049
    [Abstract] [Full Text] [Related]

  • 16. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS, Kim SH, Song KD, Choi SY, Heo NH.
    J Magn Reson Imaging; 2020 Jan 30; 51(1):70-80. PubMed ID: 31062483
    [Abstract] [Full Text] [Related]

  • 17. MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (≤3 cm) with cirrhosis and chronic viral hepatitis: a comparative study.
    Sheng RF, Zeng MS, Rao SX, Ji Y, Chen LL.
    Clin Imaging; 2014 Jan 30; 38(3):265-72. PubMed ID: 24559750
    [Abstract] [Full Text] [Related]

  • 18. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.
    Koh J, Chung YE, Nahm JH, Kim HY, Kim KS, Park YN, Kim MJ, Choi JY.
    Eur Radiol; 2016 Feb 30; 26(2):407-16. PubMed ID: 26002136
    [Abstract] [Full Text] [Related]

  • 19. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.
    Kang Y, Lee JM, Kim SH, Han JK, Choi BI.
    Radiology; 2012 Sep 30; 264(3):751-60. PubMed ID: 22798225
    [Abstract] [Full Text] [Related]

  • 20. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.
    Kim JH, Joo I, Lee JM.
    Korean J Radiol; 2019 Jul 30; 20(7):1019-1041. PubMed ID: 31270973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.